The OAK study on NSCLC patients with second-line treatment or patients with EGFR mutations found that atezolizumab did not prolong OS.[24] Therefore, the median OS observed in our cohort (14.7 months) of heavily pretreated patients was close to that observed for other pretreated and unselected NSCLC patients enrolled in phase III trials. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.